ArticleBMJ open2026
Cost-effectiveness analysis of low bone mass prevention in Chinese older men with excessive alcohol consumption: a modelling study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChina has a high disease burden of low bone mass, and elderly men with excessive alcohol consumption may be underdiagnosed and undertreated given the adverse effects on skeletal health. This study implemented an economic evaluation to assess the screening plus receiving anti-osteoporotic medication for low bone mass prevention in older men with excessive alcohol intake. DESIGN AND
settingA patient-level Markov model.
participantsChinese men aged over 60 years with excessive alcohol consumption.
interventionsReceiving screening plus medication considered with two eligibility strategies for therapy: osteoporosis and osteopenia. OUTCOMES: The quality-adjusted life-years (QALYs), lifetime cost and the incremental cost-effectiveness ratio (ICER) were calculated for different strategies relative to no screening. Scenario analyses were conducted to evaluate the cost-effectiveness associated with risk factors, study perspectives and selection of medication.
resultsFrom the healthcare perspective, the prevention strategies for men aged over 70 years were cost-effective with the ICER of $28 403/QALY for osteoporosis and $24 560/QALY for osteopenia. Scenario analyses revealed screening strategies were cost-effective in men with risk factors aged over 60 years. In the selection of medication, denosumab might be dominant. From the societal perspective, prevention for osteopenia aged from 60 years was cost-effective at the ICER of $36 524/QALY.
conclusionsThese findings suggest that prevention strategies for Chinese older men with excessive alcohol consumption would be cost-effective. Early screening initiation will aid efforts in improving skeletal health for men with excessive alcohol intake in China and reducing humanistic and economic burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.